The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Leadership continuity and global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement provides a strong regional and policy-driven outlook. The role of Secretary will be fulfilled by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing broad expertise in regulatory toxicology and global product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been appointed Treasurer, offering substantial leadership experience in toxicology and governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Driving the progress of animal-free science through collective collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment approaches, when fully refined and validated, are not only ethically sound but also offer superior scientific performance. Since its establishment in early 2023, ICCS has sought to show that non-animal methods can deliver dependable and meaningful data to safeguard both human health and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing engagement from regulators across the globe.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS contributed to the creation of innovative methodologies aligned with next generation risk assessment (NGRA), an evolving framework that combines cutting-edge in vitro, in silico, and exposure-driven techniques. These methods are increasingly recognized as vital to contemporary toxicology, providing the possibility of more human-relevant insights while decreasing dependence on animal studies. ICCS’ work in this area underscores its dedication to promoting ethical progress as well as scientific rigor.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A pivotal moment for cosmetics safety regulation
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has long stressed that advancing animal-free safety science cannot happen through fragmented initiatives; rather, it demands synchronized efforts involving industry, academia, regulators, and civil society. This approach is mirrored in the Board’s makeup, which unites leaders who grasp the technical, regulatory, and organizational aspects required to drive meaningful change.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair emphasized the importance of leveraging ICCS’ global, multi-stakeholder model to close the gap between innovation and regulation. This approach aims to ensure that advances in animal-free science are not confined to research settings but translated into practical tools that regulators can trust and apply consistently.
Strengthening foundations for long-term impact
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education continues to be a central pillar of ICCS’ strategy, with the organization striving to offer accessible, science‑grounded materials and spaces for dialogue that help clarify the principles of animal‑free safety science and support well‑informed choices. This effort becomes especially vital in a field where misunderstandings or uneven levels of expertise can hinder advancement, even when the science itself is robust.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
In confirming its 2026 Board officers, ICCS signals both stability and forward momentum. The leadership team brings continuity from a year marked by concrete achievements, alongside the experience and perspective needed to navigate the next phase of change. As scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a convener and catalyst for animal-free cosmetics safety science is set to become even more relevant.
Ultimately, the significance of the 2026 Board elections lies not only in the individuals appointed, but in what their leadership represents: a sustained commitment to collaboration, scientific integrity, and the responsible advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to translate vision into lasting impact, shaping the future of cosmetics safety in a way that aligns ethics, science, and global public trust.